Hematology

Monitoring, Prognosis, & Building Your Care Team

At a Glance

Pulmonary fibrosis-hepatic hyperplasia-bone marrow hypoplasia syndrome needs lifelong, coordinated monitoring of lung function, blood counts, and liver complications. Prognosis varies with genetics, age, and organ health, while transplant and family-testing decisions require specialized care.

Managing a multisystem condition like pulmonary fibrosis-hepatic hyperplasia-bone marrow hypoplasia syndrome requires a shift from “reactive” care (treating symptoms as they appear) to “proactive” surveillance (finding and managing issues before they become emergencies).

Because this condition is so rare, your care team must be built around a core group of specialists who understand how these systems interact ^[1].

Building Your Expert Care Team

You are the most important member of your care team, but you need a “cabinet” of specialists to guide you. Because a treatment for one organ can affect another, these doctors must communicate frequently ^[2].

Hematologist: Focuses on your “blood factory” (bone marrow), monitoring for low counts and the risk of transformation to MDS or AML ^[2].
Pulmonologist: Specializes in interstitial lung disease (ILD) to track lung scarring and oxygen needs ^[3].
Hepatologist: Monitors for unusual liver growth (nodular regenerative hyperplasia) and high pressure in the liver’s veins (portal hypertension) ^[4]^[5].
Geneticist / Genetic Counselor: Helps interpret your specific genetic variant and manages testing for family members ^[6]^[7].
Transplant Coordinator: Even if you do not need a transplant today, having a connection to a major transplant center is vital for long-term planning ^[3]^[8].

Your Surveillance Schedule

Surveillance is lifelong. While your doctors will tailor your schedule to your specific needs, the following table represents an example monitoring framework for adult Telomere Biology Disorders (TBDs). There is no single schedule for every patient ^[2]^[9].

Organ System	Key Test	What They Are Looking For	Typical Frequency
Lungs	PFTs (Spirometry & DLCO)	Declining lung capacity or oxygen transfer ^[10].	Tailored to disease stability
Marrow	CBC with Reticulocytes	Low white/red cells, platelets, or increasing cell size (macrocytosis) ^[2].	Tailored to cell counts
Liver	Abdominal Ultrasound / Elastography	Signs of liver nodules, enlarged spleen, or fluid. Note that ultrasound may not reliably characterize NRH ^[4].	Guided by hepatology
Vessels	Upper Endoscopy (EGD)	Swollen veins in the esophagus (varices) ^[11].	Guided by portal hypertension
Cancer	Skin & Oral Exam	New spots or white patches in the mouth ^[12].	Annual or personalized

Understanding Prognosis

It is natural to ask about “how long” or “how fast,” but prognosis in this syndrome is highly individual. It is influenced by your genetics, your age at diagnosis, and how well your organs are currently functioning ^[13].

Genetic Variants: Genotype-phenotype associations are variable, and while some studies track variants in the TERT or TERC genes, they should not be used as a deterministic forecast ^[14]^[15].
Marrow Health: The presence of MDS or AML (marrow malignancies) significantly changes the prognosis, making a stem cell transplant evaluation a higher priority ^[16].
Transplant Success: For many, transplantation (lung, liver, or bone marrow) offers a path to long-term survival, though these procedures carry higher risks in TBD patients and require specialized “gentle” protocols ^[17]^[18].

Family Considerations

Because this is a genetic condition, your diagnosis has implications for your biological relatives.

Cascade Testing: First-degree relatives (parents, siblings, children) should be offered genetic counseling ^[6]. Testing usually begins with a confirmed familial pathogenic variant when one is available; telomere testing is not a simple screen ^[7].
Hidden Risk: Some relatives may carry the gene but have no symptoms yet, or they may have short telomeres even if they don’t have the specific mutation ^[19]. Identifying these relatives early allows them to start their own surveillance and avoid environmental triggers like smoking, which can speed up lung damage.

Common questions in this guide

Which specialists should be involved in my care?

Care for pulmonary fibrosis-hepatic hyperplasia-bone marrow hypoplasia syndrome commonly includes a hematologist, pulmonologist, hepatologist, and geneticist or genetic counselor. A transplant center may also help with long-term planning. One clinician should coordinate communication so treatment for one organ does not create problems for another.

What monitoring tests are used for this syndrome?

Monitoring may include breathing tests called pulmonary function tests, blood counts with a reticulocyte count, liver imaging, and an upper endoscopy when high pressure in the liver veins raises concern for swollen esophageal veins. Skin and mouth examinations look for new spots or white patches. The schedule is tailored to disease stability, blood counts, and organ findings.

What factors affect the outlook for this telomere disorder?

The outlook depends on the genetic variant, age at diagnosis, and how well the lungs, liver, and bone marrow are functioning. Myelodysplastic syndrome or acute myeloid leukemia can substantially change prognosis. Genetic findings may show patterns in groups of patients but cannot predict one person's future with certainty.

Will I need a transplant?

Not everyone with this syndrome needs a transplant. Lung, liver, or blood-forming stem cell transplantation may be considered when organ or bone-marrow disease becomes severe, and marrow malignancy can make evaluation more urgent. Transplant programs experienced with telomere biology disorders can plan specialized protocols for the higher risks associated with these conditions.

Should my parents, siblings, or children have genetic testing?

First-degree relatives—parents, siblings, and children—should be offered genetic counseling because this is a genetic syndrome. If a familial disease-causing variant is known, testing usually starts with that specific variant. Telomere-length testing alone is not a simple screening test, and relatives can carry risk before symptoms appear.

When should I ask about a transplant evaluation?

A transplant discussion may be appropriate when lung or liver function is worsening, complications such as portal hypertension or swollen veins called varices develop, or bone-marrow disease becomes more serious. A transplant center can assess timing before an emergency occurs. The decision depends on organ testing, overall health, and the risks associated with telomere biology disorders.

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Pulmonary fibrosis-hepatic hyperplasia-bone marrow hypoplasia syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Curated prompts to bring to your next appointment.

1.Who is the 'lead coordinator' on my team responsible for ensuring my pulmonologist, hematologist, and hepatologist are aligned on my care?
2.Given my specific findings, what is our individualized target frequency for monitoring my lung function (PFTs) and blood counts?
3.When should we perform an endoscopy to screen for liver-related complications like varices?
4.If I develop a new clonal change in my bone marrow, at what point does it alter our treatment plan?
5.Can you refer me to a genetic counselor to discuss testing and surveillance recommendations for my first-degree relatives?
6.What are the specific signs of progression in my liver that would prompt a referral for a transplant evaluation?

Key takeaways

Lifelong, individualized surveillance includes pulmonary function tests, blood counts with reticulocytes, liver assessment, and skin and oral examinations.
Hematology, pulmonology, hepatology, genetics, and transplant specialists should communicate through a coordinated care plan.
Prognosis varies with genetic findings, age at diagnosis, organ function, and development of myelodysplastic syndrome or acute myeloid leukemia; genes do not determine an individual's outcome.
First-degree relatives should receive genetic counseling and, when available, testing for the known familial pathogenic variant; telomere testing alone is not a simple screen.
Lung, liver, or hematopoietic stem cell transplantation may be considered when disease is severe, using specialized protocols in experienced centers.

References (19)

1
Hematological complications in solid organ transplant recipients with telomere biology disorders: a narrative review.
Carlier FM, Planté-Bordeneuve T, Froidure A, et al.
Frontiers in immunology 2025; (16()):1718107 doi:10.3389/fimmu.2025.1718107.
PMID: 41624889
2
Diagnosis and management of telomere biology disorders in developing countries.
Rodríguez A, Avendaño-Robles BA, Catto MB, et al.
Seminars in hematology 2025; (62(6)):521-531 doi:10.1053/j.seminhematol.2026.04.004.
PMID: 42177138
3
Lung transplantation for interstitial lung disease.
Kapnadak SG, Raghu G
European respiratory review : an official journal of the European Respiratory Society 2021; (30(161)) doi:10.1183/16000617.0017-2021.
PMID: 34348979
4
Progression of liver disease and portal hypertension in dyskeratosis congenita and related telomere biology disorders.
Vittal A, Niewisch MR, Bhala S, et al.
Hepatology (Baltimore, Md.) 2023; (78(6)):1777-1787 doi:10.1097/HEP.0000000000000461.
PMID: 37184208
5
Telomere biology disorders and hepatic disease.
Pirzada SA, Aleyadeh W, Fathma S, et al.
Seminars in hematology 2025; (62(6)):503-512 doi:10.1053/j.seminhematol.2026.05.004.
PMID: 42215326
6
Familial pulmonary fibrosis: a UK consensus framework for the investigation and management of patients and their relatives.
Bowden AR, Morris-Rosendahl DJ, Hanson H, et al.
Thorax 2026; doi:10.1136/thorax-2026-225625.
PMID: 42722421
7
Genetic Counseling and Family Screening Recommendations in Patients with Telomere Biology Disorders.
Ongie L, Raj HA, Stevens KB
Current hematologic malignancy reports 2023; (18(6)):273-283 doi:10.1007/s11899-023-00713-8.
PMID: 37787873
8
Telomeres in Interstitial Lung Disease: The Short and the Long of It.
Courtwright AM, El-Chemaly S
Annals of the American Thoracic Society 2019; (16(2)):175-181 doi:10.1513/AnnalsATS.201808-508CME.
PMID: 30540921
9
Stem cell transplantation and gene therapy for telomere biology disorders: Historical perspective, current approaches, and emerging strategies.
Koo J, Reed HD, Myers KC, Agarwal S
Seminars in hematology 2025; (62(6)):493-502 doi:10.1053/j.seminhematol.2026.03.001.
PMID: 41916788
10
Prognostic significance of pulmonary function tests in dyskeratosis congenita, a telomere biology disorder.
Giri N, Ravichandran S, Wang Y, et al.
ERJ open research 2019; (5(4)) doi:10.1183/23120541.00209-2019.
PMID: 31754622
11
Hepatic manifestations of telomere biology disorders.
Patnaik MM, Kamath PS, Simonetto DA
Journal of hepatology 2018; (69(3)):736-743 doi:10.1016/j.jhep.2018.05.006.
PMID: 29758336
12
Genotype and Associated Cancer Risk in Individuals With Telomere Biology Disorders.
Niewisch MR, Kim J, Giri N, et al.
JAMA network open 2024; (7(12)):e2450111 doi:10.1001/jamanetworkopen.2024.50111.
PMID: 39661387
13
Germline RTEL1 Variants in Telomere Biology Disorders.
Thompson AS, Niewisch MR, Giri N, et al.
American journal of medical genetics. Part A 2025; (197(2)):e63882 doi:10.1002/ajmg.a.63882.
PMID: 39279436
14
Prevalence and characteristics of TERT and TERC mutations in suspected genetic pulmonary fibrosis.
Borie R, Tabèze L, Thabut G, et al.
The European respiratory journal 2016; (48(6)):1721-1731 doi:10.1183/13993003.02115-2015.
PMID: 27836952
15
Pulmonary fibrosis in dyskeratosis congenita: a case report with a PRISMA-compliant systematic review.
Wang P, Xu Z
BMC pulmonary medicine 2021; (21(1)):279 doi:10.1186/s12890-021-01645-w.
PMID: 34479523
16
Haematological features of telomere biology disorders diagnosed in adulthood: A French nationwide study of 127 patients.
Maillet F, Galimard JE, Borie R, et al.
British journal of haematology 2024; (205(5)):1835-1847 doi:10.1111/bjh.19767.
PMID: 39279213
17
Allogeneic Hematopoietic Cell Transplant For Bone Marrow Failure or Myelodysplastic Syndrome in Dyskeratosis Congenita/Telomere Biology Disorders: Single-Center, Single-Arm, Open-Label Trial of Reduced-Intensity Conditioning Without Radiation.
Dimitrov M, Merkle S, Cao Q, et al.
Transplantation and cellular therapy 2024; (30(10)):1005.e1-1005.e17 doi:10.1016/j.jtct.2024.07.007.
PMID: 39002862
18
Telomere biology disorders in lung transplantation: Clinical challenges and management strategies.
Mesli F, Philippot Q, El Husseini K, et al.
JHLT open 2025; (9()):100333 doi:10.1016/j.jhlto.2025.100333.
PMID: 40726990
19
Pulmonary fibrosis in non-mutation carriers of families with short telomere syndrome gene mutations.
van der Vis JJ, van der Smagt JJ, van Batenburg AA, et al.
Respirology (Carlton, Vic.) 2021; (26(12)):1160-1170 doi:10.1111/resp.14145.
PMID: 34580961

This page provides general information about monitoring, prognosis, and care-team planning for this rare syndrome; it is not medical advice. Your specialists should tailor surveillance, family counseling, and transplant planning to your situation.

Guide Contents